无创通气联合参附注射液治疗对重症哮喘合并呼吸衰竭患儿肺功能、免疫功能及PCT、IL-17和CRP的影响

摘要
图/表
参考文献
相关文章 (5)

全文: PDF (2695 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的：探讨无创通气下参附注射液对重症哮喘合并呼吸衰竭患儿的临床疗效。方法：选取2021年1月―2022年12月医院收治的重症哮喘合并呼吸衰竭患儿60例,随机数字表法分为A组（n=30）和B组（n=30）,A组行无创通气治疗,B组在A组基础上行参附注射液治疗。比较两组患儿肺功能指标、免疫功能指标、血清炎性指标及血气指标,并比较两组治疗总有效率。结果：治疗后,两组呼气峰流速（PEF）、最大呼气第一秒呼出的气量容积（FEV₁）、用力肺活量（FVC）、免疫球蛋白A（IgA）、免疫球蛋白M（IgM）及免疫球蛋白G（IgG）水平较治疗前均升高,且B组PEF、FEV₁、FVC、IgA、IgM及IgG水平高于A组;两组血清降钙素原（PCT）、白介素17（IL-17）及C反应蛋白（CRP）水平较治疗前均降低,且B组PCT、IL-17及CRP水平低于A组;两组动脉血氧分压（PaO₂）较治疗前均升高、动脉血二氧化碳分压（PaCO₂）较治疗前均降低,且B组PaO₂高于A组、PaCO₂低于A组;B组治疗总有效率与A组差异无统计学意义;但按照不同的治疗等级进行秩和检验发现,以B组的临床疗效更好,差异有统计学意义。结论：无创通气下参附注射液治疗重症哮喘合并呼吸衰竭,能有效改善患儿肺功能,具有调节免疫功能作用,减轻血清炎症反应,临床疗效较好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄凤枚
	何春
	于晓莉
	彭华保
	侯彰华
	谭若琨
	朱丽辉

关键词 ：重症哮喘合并呼吸衰竭, 参附注射液, 无创通气, 肺功能, 免疫功能, 血清炎性因子

Abstract：Objective To investigate the clinical effect of Shenfu injection on children with severe asthma and respiratory failure under non-invasive ventilation. Methods Sixty children with severe asthma complicated with respiratory failure admitted to the hospital from January 2021 to December 2022 were randomly divided into group A (n=30) and group B (n=30). Group A received non-invasive ventilation treatment, and group B was treated with injection on the basis of group A. Pulmonary function indexes, immune function indexes, serum inflammatory indexes and blood gas indexes were compared between the two groups, and the total effective rate was compared between the two groups. Results After treatment, the levels of peak expiratory flow rate (PEF), maximum volume of exhaled air in the first second of exhalation (FEV1), forced vital capacity (FVC), immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG) in both groups were increased compared with those before treatment. The levels of PEF, FEV1, FVC, IgA, IgM and IgG in group B were higher than those in group A. Serum levels of procalcitonin (PCT), interleukin17(IL-17) and C-reactive protein (CRP) in 2 groups were lower than before treatment, and the levels of PCT, IL-17 and CRP in group B were lower than those in group A). Arterial partial pressure of oxygen (PaO₂) increased and arterial partial pressure of carbon dioxide (PaCO₂) decreased in both groups compared with before treatment, and PaO₂ in group B was higher than that in group A and PaCO₂ was lower than that in group A. There was no significant difference in the total effective rate between group B and group A. However, according to the rank sum test of different treatment grades, the clinical efficacy of group B was better, and the difference was statistically significant. Conclusion In the treatment of severe asthma complicated with respiratory failure with non-invasive ventilation, Shenfu injection can effectively improve lung function, regulate immune function, reduce serum inflammatory response, and has a good clinical effect.

Key words： severe asthma with respiratory failure shenfu injection non invasive ventilation lung function immunity serum inflammatory factor

收稿日期: 2023-02-28

中图分类号:

R562.2+5

基金资助:2022年郴州市第一人民医院院级课题（JG2022-015）

通讯作者: 朱丽辉,E-mail：877845375@qq.com

引用本文:

黄凤枚, 何春, 于晓莉, 彭华保, 侯彰华, 谭若琨, 朱丽辉. 无创通气联合参附注射液治疗对重症哮喘合并呼吸衰竭患儿肺功能、免疫功能及PCT、IL-17和CRP的影响[J]. 金宝搏官方188学报(医学版), 2023, 20(3): 66-70. HUANG Fengmei, HE Chun, YU Xiaoli, PENG Huabao, HOU ZhangHua, TAN Ruokun, ZHU Lihui. Effects of non-invasive ventilation combined with shenfu injection on lung function, immune function, PCT, IL-17 and CRP in children with severe asthma complicated with respiratory failure. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 66-70.

链接本文:

http://yxb.hunnu.edu.cn/CN/ 或 http://yxb.hunnu.edu.cn/CN/Y2023/V20/I3/66

[1] Gon Y, Hashimoto S.Role of airway epithelial barrier dysfunction in pathogenesis of asthma[J]. Allergol Int, 2018, 67(1) : 12-17.
[2] Haktanir Abul M, Phipatanakul W.Severe asthma in children: evaluation and management[J]. Allergol Int, 2019, 68(2) : 150-157.
[3] Vásquez-Hoyos P, Jiménez-Chaves A, Tovar-Velásquez M, et al.Factors associated to high-flow nasal cannula treatment failure in pediatric patients with respiratory failure in two pediatric intensive care units at high altitude. Factores asociados al fracaso de la terapia con cánulas nasales de alto flujo en pacientes pediátricos con insuficiencia respiratoria en dos unidades de cuidados críticos pediátricos a gran altitud[J]. Med Intensiva (Engl Ed) , 2021, 45(4) : 195-204.
[4] Bonnesen B, Jensen JS, Jeschke KN, et al.Management of COVID-19-associated acute respiratory failure with alternatives to invasive mechanical ventilation: high-flow oxygen, continuous positive airway pressure, and noninvasive ventilation[J]. Diagnostics (Basel) , 2021, 11(12) : 2259.
[5] Huang P, Lin X, Liu Y, et al.The efficacy and safety of combined traditional chinese and western medicine in the treatment of chronic obstructive pulmonary disease complicated with respiratory failure: a systematic review and meta-analysis study[J]. Ann Palliat Med, 2022, 11(3) : 1102-1111.
[6] Gao Y, Gao Y, Zhu R, et al.Shenfu injection combined with furosemide in the treatment of chronic heart failure in patients with coronary heart disease: a protocol of randomized controlled trial[J]. Medicine (Baltimore) , 2021, 100(3) : e24113.
[7] 洪建国. 中国儿童支气管哮喘防治指南修订要点的探讨[J]. 临床儿科杂志, 2014, 32(2) : 101-103.
[8] 肖影, 青刚. BIPAP联合特布他林雾化吸入治疗老年性重症哮喘合并呼吸衰竭疗效及对患者肺功能和免疫功能的影响[J]. 金宝搏官方188学报 (医学版) , 2022, 19(4) : 77-81.
[9] Pilar J, Modesto I Alapont V, Lopez-Fernandez YM, et al. High-flow nasal cannula therapy versus non-invasive ventilation in children with severe acute asthma exacerbation: an observational cohort study[J]. Med Intensiva, 2017, 41(7) : 418-424.
[10] 张奕, 马立霜, 曹玲, 等. 先天性膈疝患儿手术后近期肺功能观察及相关因素分析[J]. 临床小儿外科杂志, 2022, 21(03) : 236-241.
[11] 金佩伦, 李武峰, 李诗国, 等. 丹红注射液联合无创正压通气对重症哮喘并呼吸衰竭患者凝血状态及体液免疫的影响[J]. 中国药物与临床, 2019, 19(3) : 425-427.
[12] 周梦雪, 罗健. 肺功能检查在小儿外科术前评估中的应用研究进展[J]. 临床小儿外科杂志, 2021, 20(04) : 382-387.
[13] Li X, Lin H, Wang Q, et al.Chemical composition and pharmacological mechanism of shenfu decoction in the treatment of novel coronavirus pneumonia (COVID-19)[J]. Drug Dev Ind Pharm, 2020, 46(12) : 1947-1959.
[14] Mandlik DS, Mandlik SK.New perspectives in bronchial asthma: pathological, immunological alterations, biological targets, and pharmacotherapy[J]. Immunopharmacol Immunotoxicol, 2020, 42(6) : 521-544.
[15] Miyazaki H, Nagata N, Akagi T, et al.Comprehensive analysis of prognostic factors in hospitalized patients with pneumonia occurring outside hospital: Serum albumin is not less important than pneumonia severity assessment scale[J]. J Infect Chemother, 2018, 24(8) : 602-609.
[16] Chen D, Zhang Y, Yao C, et al.Increased levels of serum IL-17 and induced sputum neutrophil percentage are associated with severe early-onset asthma in adults[J]. Allergy Asthma Clin Immunol, 2021, 17(1) : 64.
[17] Ruihong Z, Lu W, Xiaoli L. Effect of terbutaline combined with budesonide in treatment of bronchial asthma and rehabilitation nursing[J]. Pak J Pharm Sci, 2018, 31 (5 (Special) ) : 2249-2255.
[18] Pei H, Ma Y, Wang L, et al.Effects of shenfu injection on inflammatory factors and immune function in children with mycoplasma pneumoniae: a protocol for a double-blind, randomized controlled trial[J]. Medicine (Baltimore) , 2021, 100(42) : e27585.
[19] 齐亚丽, 李婷, 池燕. 噻托溴铵干粉吸入联合多索茶碱对重症支气管哮喘合并呼吸衰竭患者血气指标及血清超敏C反应蛋白、肿瘤坏死因子α水平影响[J]. 创伤与急危重病医学, 2021, 9 (5) : 400-402+405.